Global Stem Cells Group (GSCG) and ReGen are thrilled to announce the grand opening of a new franchise clinic in Tashkent, Uzbekistan. The inauguration ceremony, attended by distinguished leaders in the field of regenerative medicine, marks a momentous occasion for healthcare in the region.
The event was graced by the presence of Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA), and Benito Novas, the Director of Public Relations for both GSCG and ISSCA.
In addition to celebrating the clinic’s opening, the Tashkent center hosted the first ISSCA training program in the region, providing local physicians with the latest advancements in regenerative medicine.
Dr. Salih Yildirim expressed his delight, stating, “After inaugurating clinics in Istanbul (Turkey), Buenos Aires (Argentina), Cancun (Mexico), Miami (USA), and Jakarta (Indonesia), we are now here in Uzbekistan, in Tashkent. This moment fills me with great joy and a profound sense of purpose. It is a privilege to bring the benefits of regenerative medicine to the people of Uzbekistan”
Benito Novas added, “This is impressive. In the field of regenerative medicine, we aim to expand the movement, benefiting not only local patients but patients worldwide. This will undoubtedly be a great success. Regenerative medicine is not just the medicine of the future; it’s the medicine of the present.”
The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region.
Partnership Between Global Stem Cells Group and ReGen
Through their strategic partnership, ReGen has experienced remarkable growth, leveraging Global Stem Cells Group’s reputation and extensive resources to open state-of-the-art clinics in several countries. These clinics have become pioneers in regenerative care in the region.
ReGen is at the forefront of introducing cutting-edge aesthetic treatments, such as the perfected hair transplant technique from Turkey, revolutionizing the regenerative healthcare landscape. Patients now have access to the latest and most effective treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.
While ReGen brings access to clinics, advanced techniques and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.
This landmark partnership is poised to reshape the world of regenerative care, marking a transformative moment for the field of regenerative medicine.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
ReGen is a highly acclaimed Turkish company with clinics in Turkey and in several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
For further information, please contact:
Telephone: (800) 956-3935